Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H
Research Center, Nihon Nohyaku Co., Ltd., Kawachinagano, Osaka, Japan.
Antimicrob Agents Chemother. 1998 Apr;42(4):967-70. doi: 10.1128/AAC.42.4.967.
In vitro and in vivo antidermatophyte activities of NND-502, a new imidazole antimycotic agent, were compared with those of two existing antifungal agents, lanoconazole and terbinafine. NND-502 exhibited strong in vitro antifungal activity against Trichophyton spp.; its MIC was 1 to 4 times lower than that of lanoconazole or terbinafine. In an in vivo study with a guinea pig model of tinea pedis, 7-day topical treatment with a 0.5% solution of NND-502 (dissolved in polyethylene glycol 400) was more effective than that with a 0.5% solution of either lanoconazole or terbinafine for eradicating fungi from the infected feet. When the duration of treatment was shortened to 3 days, a topical 1% solution of NND-502 achieved a complete mycological cure, while topical 1% solutions of lanoconazole and terbinafine did not.
将新型咪唑类抗真菌剂NND - 502的体外和体内抗皮肤癣菌活性与两种现有抗真菌剂——兰诺康唑和特比萘芬进行了比较。NND - 502对毛癣菌属表现出较强的体外抗真菌活性;其最低抑菌浓度(MIC)比兰诺康唑或特比萘芬低1至4倍。在豚鼠足癣模型的体内研究中,用0.5%的NND - 502溶液(溶于聚乙二醇400)进行7天局部治疗,在清除感染足部真菌方面比用0.5%的兰诺康唑或特比萘芬溶液更有效。当治疗时间缩短至3天时,局部使用1%的NND - 502溶液可实现完全真菌学治愈,而局部使用1%的兰诺康唑和特比萘芬溶液则不能。